Inotek Pharmaceuticals appoints Pat Machado to the Board of Directors and its Audit Committee

– USA, MA – Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Patrick Machado, JD, has been appointed to its Board of Directors. Mr. Machado will serve on the Audit Committee.

Mr. Machado most recently served as Co-Founder, Chief Business Officer and Chief Financial Officer of Medivation, Inc. (NASDAQ: MDVN), a biopharmaceutical company, for 11 years. At Medivation, Mr. Machado led the company through a period of substantial financial and clinical growth while managing all business development, financial, operations and legal functions of the company. Mr. Machado’s affiliations prior to Medivation included Cytyc Health Corporation, ProDuct Health, Inc., and Chiron Corporation.

Mr. Machado earned a JD, Cum Laude, from Harvard Law School and a BA and BS, Summa Cum Laude, in German and Economics, respectively, from Santa Clara University. He currently serves as a member of the Board of Directors of Medivation, Inc., Chimerix, Inc. (NASDAQ: CMRX), and Scynexis, Inc. (NASDAQ: SCYX).

“I am delighted to welcome Pat to Inotek’s Board of Directors,” said David P. Southwell, President and Chief Executive Officer. “Mr. Machado’s diverse and extensive experience guiding late-stage biopharmaceutical companies through all stages of growth will be very valuable to us, as we grow Inotek with the development of trabodenoson.”

“Inotek’s promising pipeline of ocular disease therapies has great potential to become innovative and convenient treatment options for patients suffering from glaucoma and other eye disorders,” said Mr. Machado. “I look forward to providing strategic guidance to the Inotek team during this critical stage of trabodenoson’s development.”

About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>